Laurus Labs Limited — Capital/Financing Update 2023

Sep 11, 2023

September 11, 2023

==> picture [452 x 75] intentionally omitted <==

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25thFloor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited, Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sirs,

This is to inform that the Company has signed Share Purchase Agreements today with one of the Promoters and non-executive director and his family members and also with few employees/ex-employee shareholders of Laurus Bio Pvt. Ltd. for purchase of 37,641 equity shares through secondary purchase.

With this acquisition, the shareholding of the Company in Laurus Bio Pvt. Ltd. will become 87.58% on fully diluted basis (including outstanding share warrants and ESOP Pool).

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Part A of Schedule III of the aforesaid regulations read with SEBI Circular No.CIR/CFD/CMD/4/2015 dated September 9, 2015, is also attached as per ‘Annexure’.

This is for your information and record.

Yours faithfully,

For Laurus Labs Limited

VENKATESWAR Digitally signed by VENKATESWAR REDDY GOGIREDDY REDDY GOGIREDDY Date: 2023.09.11 18:18:20 +05'30'

G. Venkateswar Reddy Company Secretary

==> picture [452 x 43] intentionally omitted <==

Annexure

==> picture [452 x 75] intentionally omitted <==

Disclosure under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

a) Name of the target entity, details in brief such as size, turnover etc.;	Laurus Bio Private Limited (“Laurus Bio”) Turnover for FY 2020-21: Rs. 52.30 Cr Turnover for FY 2021-22: Rs. 100.27 Cr Turnover for FY 2022-23: Rs. 128.62 Cr
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “armslength”;	No
c) Industry to which the entity being acquired belongs;	Bio-technology
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity);	Increase of shareholding by the Company is the effect.
e) Brief details of any governmental or regulatory approvals required for the acquisition;	No governmental or regulatory approvals required
f) Indicative time period for completion of the acquisition;	Approximately one month to 45 days, subject to completionofConditionsPrecedent
g) Nature of consideration - whether cash consideration or share swap and details of the same;	Cash consideration only
h) Cost of acquisition or the price at which the shares are acquired;	Rs.71.60 Crore (approximately)
i) Percentage of shareholding / control acquired and/or number of shares acquired;	37,641 equity share of face value of Rs.10/- each.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information(in brief);	Date of Incorporation: Turnover: FY 2022-23: Rs. 128. 62 Cr FY 2021-22: Rs. 100.27 Cr FY 2020-21:Rs. 52.30 Cr

==> picture [452 x 43] intentionally omitted <==